TSXV:BTI.H - Post by User
Post by
prophetoffactzon May 15, 2023 3:16pm
812 Views
Post# 35448844
Moment of truth:
Moment of truth:The S&P Biotech ETF is ~10% higher than where it was when the Biodexa agreement was announced. The biotech market is significantly more favorable. Biodexa promoted BTI's licensing deals and Chiesi and the J&J option were probably the reason why. Chiesi now has a strategic position in LSDs given the recent approval of Fabry in the US and Europe. The brain is of strategic interest for LSDs. J&J has advanced and expanded its xB3 deal since the Biodexa deal I believe Rathjen said at the AGM. A multi-product licensing deal with J&J could serve as major validation for xB3. The brain has never been so hot given recent Alzheimer's data and RNAi. BTI was the main attraction by valuation in the Biodexa deal and Midatech secured a financing. BTI's technology could be used with Biodexa's technology. There is also the Neuramedy deal.
We are suppose to get a Saltarelli out of this company. He stayed for a reason. He doesn't have to be here. He's on Chiesi's xB3 Advisory Board. He thinks xB3 works equal to or better than DNLI's technology. With Biodexa they aimed for creating the biggest opportunity for a biotech of its size. The brain is hotter than its ever been given recent advances. There should be $30-$50-$75 million in value in BTI's options in the near term.